Monthly Sales Imply Amvuttra Tracking Inline With Consensus

Research evidence excerpt

Monthly Sales Imply Amvuttra Tracking Inline With Consensus

Idea

June 29, 2026 12:07 PM GMT

Morgan Stanley & Co. LLCMAlnylam Pharmaceuticals Inc | North America Michael E Ulz

Equity Analyst

Monthly Sales Imply Amvuttra Mike.Ulz@morganstanley.comAvraham Novick +1 212 761-4650

Research Associate

Avi.Novick@morganstanley.com +1 212 761-2231

Tracking Inline With Consensus Rohit Bhasin

Rohit.Bhasin@morganstanley.com +1 212 761-0534

Our sales analysis shows 2Q26 Amvuttra and total TTR sales

tracking inline with consensus. As a reminder, Alnylam expects Alnylam Pharmaceuticals Inc (ALNY.O, ALNY US)

growth to accelerate for the franchise in 2Q26 following Biotechnology | United States of America

Stock Rating Equal-weight

seasonal headwinds in 1Q26 and reiterated FY26 TTR sales Industry View Attractive

Price target $370.00

guidance as underlying fundamentals remain strong. Shr price, close (Jun 26, 2026) $291.37

Mkt cap, curr (mm) $39,243

52-Week Range $495.55-273.11

Key Takeaways

Our monthly sales analysis implies 2Q26 Amvuttra sales are tracking inline with

consensus (~$1,068M vs. Cons: $1,052M).

Based on US sales data, we estimate 2Q26 WW TTR Franchise sales of ~

$1,093M tracking inline with consensus ($1,076M) as well.

This, combined with our recent script analysis, suggests 2Q26 TTR sales (~

$1,044-1,093M) are tracking inline to slightly below consensus.

Monthly sales analysis (IQVIA) indicates 2Q26 Amvuttra sales tracking inline

with consensus. We analyzed IQVIA monthly sales estimates for April/May ( Exhibit

1 ) and estimate sales for June to predict US Amvuttra sales for 2Q26. As a reminder,

Amvuttra sales growth has been driven by TTR-CM approval last year and growth

continued in May +5% m/m ( Exhibit 2 ). Our sales analysis implies 2Q26 US